Glaucoma associated with Boston type I keratoprosthesis.

摘要: The Boston Type I keratoprosthesis (KPro), approved for use by the FDA in 1992, was developed patients who are poor candidates traditional full-thickness corneal transplantation because of a high risk graft failure or rejection. indications KPro implantation include recurrent failure, herpetic disease and limbal stem cell deficiency secondary to chemical burns aniridia. Initial associated with outcomes related implant extrusion, necrosis endophthalmitis.1 As modifications design postoperative management have evolved, retention rates dramatically improved, making procedure an increasingly accepted alternative standard keratoplasty eyes unacceptably failure.2 With reduction acute complications, long term visual after surgery still limited chronic diseases, such as glaucoma. The purpose this study review clinical experience at one institution using evaluate development progression glaucoma following these patients.